-
Publication Venue For
-
Means of suicide in psychiatric patients: Population-based data from Israel between 2001 and 2020..
243:118-119.
2022
-
Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study..
224:40-44.
2020
-
Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia..
171:187-194.
2016
-
Linkage analysis of schizophrenia in African-American families..
109:70-79.
2009
-
CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al..
107:327-329.
2009
-
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function..
107:275-285.
2009
-
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial..
107:22-29.
2009
-
Results of phase 3 of the CATIE schizophrenia trial..
107:1-12.
2009
-
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study..
105:175-187.
2008
-
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study..
105:1-9.
2008
-
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1..
103:104-109.
2008
-
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)..
102:108-115.
2008
-
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1..
101:273-286.
2008
-
Neural bases of different cognitive strategies for facial affect processing in schizophrenia..
100:191-205.
2008
-
The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder..
100:60-69.
2008
-
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study..
100:39-52.
2008
-
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
2008
-
A pilot study of a weight management program with food provision in schizophrenia..
96:198-205.
2007
-
Effectiveness of atypical antipsychotics for substance use in schizophrenia patients..
94:114-118.
2007
-
Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs..
94:45-49.
2007
-
Reduction of synapsin III in the prefrontal cortex of individuals with schizophrenia..
94:366-370.
2007
-
Interpersonal trauma, war zone exposure, and posttraumatic stress disorder among veterans with schizophrenia..
91:210-216.
2007
-
Erratum to "Project among African-Americans to explore risks for schizophrenia (PAARTNERS): Recruitment and assessment methods" [Schizophrenia Research 87 (1-3) (2006) 32-44] (DOI:10.1016/j.schres.2006.06.027).
90:369.
2007
-
A longitudinal study of neurocognitive function in individuals at-risk for psychosis..
88:26-35.
2006
-
Project among African-Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods..
87:32-44.
2006
-
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline..
86:15-22.
2006
-
Olanzapine and haloperidol in first episode psychosis: two-year data..
86:234-243.
2006
-
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine..
86:244-250.
2006
-
Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring..
85:106-112.
2006
-
Comorbid posttraumatic stress disorder is associated with suicidality in male veterans with schizophrenia or schizoaffective disorder..
84:165-169.
2006
-
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode..
83:53-63.
2006
-
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder..
81:311-316.
2006
-
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia..
81:1-15.
2006
-
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial..
80:33-43.
2005
-
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial..
80:1-8.
2005
-
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III..
80:19-32.
2005
-
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome..
80:9-18.
2005
-
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode..
78:161-169.
2005
-
Obsessive compulsive symptoms in schizophrenia: frequency and clinical features..
76:309-316.
2005
-
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.
80:45-53.
2005
-
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation [3].
76:127-129.
2005
-
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia..
72:249-258.
2005
-
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery..
68:283-297.
2004
-
Abnormalities in MRI-measured signal intensity in the corpus callosum in schizophrenia..
67:277-282.
2004
-
Neuropsychological status of subjects at high risk for a first episode of psychosis..
67:115-122.
2004
-
Wisconsin Card Sorting Test performance in schizophrenia: the role of working memory..
63:201-217.
2003
-
Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia..
60:9-12.
2003
-
Working memory and schizophrenia: evidence for slowed encoding..
59:99-113.
2003
-
Decreased left amygdala and hippocampal volumes in young offspring at risk for schizophrenia..
58:173-183.
2002
-
Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources..
57:51-67.
2002
-
Outcome in children with fetal mild ventriculomegaly: a case series..
48:219-226.
2001
-
IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness..
46:203-207.
2000
-
Test-retest reliability of the dot test of visuospatial working memory in patients with schizophrenia and controls..
45:169-173.
2000
-
Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia..
41:389-395.
2000
-
Visuospatial working memory in schizotypal personality disorder patients..
41:447-455.
2000
-
Mild ventriculomegaly detected in utero with ultrasound: clinical associations and implications for schizophrenia..
33:133-140.
1998
-
Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia?.
29:36-36.
1998
-
Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia..
26:139-146.
1997
-
Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay..
26:9-14.
1997
-
Self-monitoring deficits in schizophrenia: Autonoetic agnosia.
24:110-110.
1997
-
D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder..
20:29-32.
1996
-
Fetal brain development of twins assessed in utero by ultrasound: implications for schizophrenia..
19:141-149.
1996
-
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia..
17:25-33.
1995
-
Cognitive impairment as a target for pharmacological treatment in schizophrenia..
17:123-129.
1995
-
The relationship between working memory deficits and other measures sensitive to prefrontal dysfunction.
15:123-123.
1995
-
Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function..
11:217-224.
1994
-
CLOZAPINE DECREASES DRIVE TO SMOKE.
11:104-104.
1994
-
Association between genetic variation at the porphobilinogen deaminase gene and schizophrenia..
8:211-221.
1993
-
Dopaminergic correlates of attentional performance in unmedicated schizophrenic patients.
6:136-136.
1992
-
Frontal functioning and plasma HVA in the relatives of schizophrenic patients.
6:158-158.
1992
-
Twin studies of psychopathology: why do the concordance rates vary?.
5:211-221.
1991
-
Kraepelinian schizophrenia: A replication in an independent sample.
4:257-257.
1991
-
Plasma HVA correlates of attentional performance in unmedicated schizophrenics.
4:345-346.
1991
-
Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms..
4:71-79.
1991
-
DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA
2012
-
LONGITUDINAL SUBSTANCE USE TRAJECTORIES FOR PERSONS WITH SCHIZOPHRENIA
2012
-
Poster #143 AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION
2012
-
Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR?
2012
-
COGNITIVE DYSFUNCTION AND COMMUNITY FUNCTIONING IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS)
2010
-
GABA AND GLUTAMATE-GLUTAMINE LEVELS IN THE FRONTAL CORTEX IN SCHIZOPHRENIA: A MAGNETIC RESONANCE SPECTROSCOPY STUDY
2010
-
STATIC AND DYNAMIC COGNITIVE DEFICITS IN CHILDHOOD PRECEDE ADULT SCHIZOPHRENIA: A 30-YEAR STUDY
2010
-
The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison
2006
-
A program to include persons after first psychotic episode in national service
2004
-
Self-reported drug abuse in male adolescents with behavioural disturbances and follow-up for future schizophrenia
2004
-
Functional outcomes and characteristics of olanzapine cognitive super-responders
2004
-
Is cognitive improvement with antipsychotic treatment pseudospecific?
2004
-
Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis
2004
-
Poor executive function at age 13 predicts later schizophreniform disorder: A longitudinal birth cohort study
2004
-
The brief assessment of cognition in schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery
2004
-
The functional hurdle: Connecting through cognition
2004
-
Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects
2004
-
Neurosteroid modulation of GABAergic neurotransmission in the central amygdala
2003
-
A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia
2003
-
Cannabis use in adolescence and risk for adult psychosis: A birth cohort study
2003
-
Comparison of Golgi stains of human and non-human primates
2003
-
Functional MRI assessment of atypical and conventional antipsychotic effects on cognitive function in schizophrenia patients
2003
-
Improved attention is associated with reductions in frontal lobe lactate levels in first episode psychosis
2003
-
Increased risk for schizophrenia in siblings of patients with schizotypal personality disorder
2003
-
Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis
2003
-
Recall bias in patients with schizophrenia
2003
-
Schizophrenic-like deficits in nonpsychotic children and adolescents with 22Q11 deletion syndrome
2003
-
Childhood developmental risk factors for schizophrenia and other psychiatric disorders in the Dunedin birth cohort
2001
-
Cognitive performance in first episode psychotic patients - A comparison of premorbid and morbid functioning
2001
-
Intellectual and behavioral functioning in schizophrenia patients and their unaffected siblings: A population based historical prospective cohort study
2001
-
Neonatal cerebral ventricle volume: A comparison of 3D ultrasound and MRI
2001
-
Treatment of neurocognitive deficits with olanzapine or low-dose haloperidol in first episode psychosis
2001
-
Outcome in children with fetal isolated mild ventriculomegaly: A case study
1999
-
Successful treatment of self-monitoring deficits predicts psychotic symptom decrease
1999
-
Laboratory and clinical tests of spatial working memory
1996
-
RISPERIDONE IN ELDERLY SCHIZOPHRENIC-PATIENTS
1994
-
THE EXTENT OF WORKING-MEMORY DEMANDS PREDICTS RESPONSE TO NEUROLEPTIC MEDICATION ON CONTINUOUS PERFORMANCE TESTS
1994
-
WORKING-MEMORY DEFICITS IN SCHIZOPHRENICS WITH SEVERE SELF-CARE DYSFUNCTION
1994